BioStock: Xintela’s CEO on successful studies and approved GMP facility

May has been an eventful month for Xintela with a steady stream of good news, including positive preclinical results that show that the company’s stem cell product XSTEM repairs damaged cartilage in an animal model and has great potential to become a so-called DMOAD (disease modifying osteoarthritis drug). Shortly after that, Xintela announced that it had chosen difficult-to-heal (chronic) wounds as a new indication, and that XSTEM had already shown excellent wound healing ability in a preclinical wound model. More recently, Xintela also received permission from the Medical Products Agency to produce cell therapy products in its own GMP facility, which means that production of XSTEM will now begin for clinical studies.

Read the full article at biostock.se: 

https://www.biostock.se/en/xintelas-ceo-on-successful-studies-and-approved-gmp-facility/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se